$-0.02 EPS Expected for Enzo Biochem, Inc. (ENZ)

December 8, 2017 - By Marie Mckinney

 $ 0.02 EPS Expected for Enzo Biochem, Inc. (ENZ)
Investors sentiment increased to 1.59 in Q2 2017. Its up 0.30, from 1.29 in 2017Q1. It increased, as 12 investors sold Enzo Biochem, Inc. shares while 27 reduced holdings. 28 funds opened positions while 34 raised stakes. 25.22 million shares or 2.12% more from 24.70 million shares in 2017Q1 were reported.
Barclays Public Ltd Co invested 0% of its portfolio in Enzo Biochem, Inc. (NYSE:ENZ). Mckinley Management Ltd Liability Corporation Delaware reported 455,042 shares. Eam Lc reported 0.29% stake. Moreover, Brookstone Cap has 0.02% invested in Enzo Biochem, Inc. (NYSE:ENZ) for 20,000 shares. Creative Planning has 0% invested in Enzo Biochem, Inc. (NYSE:ENZ) for 31 shares. Raymond James Tru Na holds 30,000 shares. Art Advisors Ltd Limited Liability Company reported 10,573 shares. Two Sigma Secs Limited Liability Corporation holds 0.02% of its portfolio in Enzo Biochem, Inc. (NYSE:ENZ) for 10,830 shares. Metropolitan Life Insur Communication Ny holds 0% or 31,831 shares in its portfolio. California Pub Employees Retirement owns 56,941 shares for 0% of their portfolio. 144,727 were accumulated by Invesco. Susquehanna Gru Limited Liability Partnership, Pennsylvania-based fund reported 66,452 shares. Renaissance Ltd Liability holds 0.03% in Enzo Biochem, Inc. (NYSE:ENZ) or 2.07 million shares. City Hldg holds 0% or 120 shares in its portfolio. Panagora Asset holds 0.02% or 474,237 shares.

Since June 13, 2017, it had 0 insider purchases, and 1 insider sale for $160,054 activity.

Analysts expect Enzo Biochem, Inc. (NYSE:ENZ) to report $-0.02 EPS on December, 14.They anticipate $0.01 EPS change or 33.33 % from last quarter’s $-0.03 EPS. The stock increased 2.59% or $0.24 during the last trading session, reaching $9.51. About 170,018 shares traded. Enzo Biochem, Inc. (NYSE:ENZ) has risen 44.32% since December 8, 2016 and is uptrending. It has outperformed by 27.62% the S&P500.

Enzo Biochem, Inc., an integrated diagnostic bioscience company, engages in the research, development, manufacture, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. The company has market cap of $446.26 million. The firm operates in three divisions: Clinical Labs, Life Sciences, and Therapeutics. It currently has negative earnings. The Clinical Labs segment provides routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication levels, and search for an otherwise undiagnosed condition.

More notable recent Enzo Biochem, Inc. (NYSE:ENZ) news were published by: Seekingalpha.com which released: “Enzo Biochem Rounds The Corner” on July 10, 2017, also Businesswire.com with their article: “Enzo Biochem Reports Improved First Quarter Results” published on December 07, 2017, Businesswire.com published: “Enzo Biochem Schedules Teleconference to Discuss First Quarter 2018 Results …” on December 05, 2017. More interesting news about Enzo Biochem, Inc. (NYSE:ENZ) were released by: Seekingalpha.com and their article: “Enzo Biochem (ENZ) on Q3 2017 Results – Earnings Call Transcript” published on June 09, 2017 as well as Businesswire.com‘s news article titled: “Enzo Biochem Announces NYS Department of Health’s Approval of a New Women’s …” with publication date: October 23, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: